Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995391 | 0.96 | DPP4 (0.43) | DPP4DPP8HSD17B10DPP7PARP1 | |
| SCHEMBL14850713 | 0.90 | MAPK1 (0.41) | DPP4HSD17B10PARP1 | |
| SCHEMBL1343400 | 0.90 | MAPK1 (0.41) | DPP4HSD17B10PARP1 | |
| SCHEMBL19474636 | 0.90 | MAPK1 (0.41) | DPP4HSD17B10PARP1 | |
| SCHEMBL22128107 | 0.78 | HSD17B10 (0.41) | HSD17B10HPGDPARP1 | |
| SCHEMBL22120434 | 0.78 | HSD17B10 (0.41) | HSD17B10HPGDPARP1 | |
| SCHEMBL4766170 | 0.76 | HSD17B10 (0.42) | HSD17B10HPGD | |
| SCHEMBL3805159 | 0.76 | HSD17B10 (0.42) | HSD17B10HPGD | |
| SCHEMBL17596640 | 0.75 | MAPK1 (0.41) | HSD17B10PARP1 | |
| SCHEMBL17596585 | 0.75 | MAPK1 (0.41) | HSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992022279-A2 | N-[ARYLETHYL]-N-ALKYL-2-(1-PYRROLIDINYL)ETHYLAMINE DERIVATIVES FOR CNS DISORDERS | G.D. SEARLE & CO. (US) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518216-A2 | N-/Arylethyl/-N-alkyl-2-(1-pyrrolidinyl)ethylamine derivatives for CNS disorders | G.D. Searle & Co. (US) | 1992-12-16 | — | — | EP | disclosed |